Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Infectious Diseases Singapore

Drug Prices, Trade Deal Hot For 1st Democratic Debate

This article was originally published in Scrip

Executive Summary

Prescription drug prices and the Trans-Pacific Partnership (TPP) are sure bets to be among the hot cards played on Oct. 13 in Las Vegas at the first of six debates among the 2016 Democratic contenders, former secretary of State Hillary Clinton, Sen. Bernie Sanders (I-VT) and those three other guys – former Maryland governor Martin O'Malley and former US senators James Webb (VA) and Lincoln Chafee (RI).

Table

View full table

Topics

Related Companies

Tags:
Infectious Diseases Singapore
Latest Headlines

Pipeline Watch: Eighteen Approvals And Six Phase III Trial Updates

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

See All
UsernamePublicRestriction

Register

SC030022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By